A carregar...
Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn’s Disease or Ulcerative Colitis
BACKGROUND AND AIMS: Vedolizumab was shown to be safe and effective for the treatment of Crohn’s disease [CD] and ulcerative colitis [UC] in the GEMINI Long-Term Safety [LTS] study. The vedolizumab Extended Access Program [XAP] provides patients with continued treatment. This XAP pharmacokinetics [P...
Na minha lista:
| Publicado no: | J Crohns Colitis |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7476636/ https://ncbi.nlm.nih.gov/pubmed/32060515 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ecco-jcc/jjaa027 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|